STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

A new stroke therapy which delivers electrical pulses to the brain via a portable, pacemaker-type device during rehabilitation therapy will be tested in a pioneering trial. It represents an attempt to ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...